OVID Stock Summary and Trading Ideas (Ovid Therapeutics | NASDAQ:OVID)

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ovid Therapeutics trades on the NASDAQ stock market under the symbol OVID.

As of September 4, 2026, OVID stock price climbed to $2.80 with 1,045,494 million shares trading.

OVID has a beta of 1.32, meaning it tends to be more sensitive to market movements. OVID has a correlation of 0.04 to the broad based SPY ETF.

OVID has a market cap of $546.83 million. This is considered a Small Cap stock.

Last quarter Ovid Therapeutics reported $733,000 in Revenue and -$.08 earnings per share. This beat revenue expectation by $703,000 and exceeded earnings estimates by $.02.

In the last 3 years, OVID traded as high as $4.10 and as low as $.24.

The top ETF exchange traded funds that OVID belongs to (by Net Assets): XBI, VTI, VXF, VTWO, FESM.

OVID has outperformed the market in the last year with a return of +117.1%, while the SPY ETF gained +19.8%. In the last 3 month period, OVID beat the market returning +12.9%, while SPY returned +2.0%. However, in the most recent 2 weeks OVID has underperformed the stock market by returning 0.0%, while SPY returned +0.6%.

OVID support price is $2.69 and resistance is $2.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OVID shares will trade within this expected range on the day.